Abstract
Fatty acid amide hydrolase (FAAH) degrades neuromodulating fatty acid amides including anandamide (endogenous cannabinoid agonist) and oleamide (sleep-inducing lipid) at their sites of action and is intimately involved in their regulation. Herein we report the discovery of a potent, selective, and efficacious class of reversible FAAH inhibitors that produce analgesia in animal models validating a new therapeutic target for pain intervention. Key to the useful inhibitor discovery was the routine implementation of a proteomics-wide selectivity screen against the serine hydrolase superfamily ensuring selectivity for FAAH coupled with systematic in vivo examinations of candidate inhibitors.
Original language | English (US) |
---|---|
Pages (from-to) | 1849-1856 |
Number of pages | 8 |
Journal | Journal of medicinal chemistry |
Volume | 48 |
Issue number | 6 |
DOIs | |
State | Published - Mar 24 2005 |